Modality
siRNA
MOA
SOS1i
Target
GLP-1R
Pathway
T-cell
ThymomaEwing SarcomaLN
Development Pipeline
Preclinical
~Sep 2015
→ ~Dec 2016
Phase 1
Mar 2017
→ Aug 2030
Phase 1Current
NCT05171695
937 pts·Thymoma
2017-03→2030-08·Not yet recruiting
937 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-08-164.4y awayPh2 Data· Thymoma
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P1/2
Not yet…
Catalysts
Ph2 Data
2030-08-16 · 4.4y away
Thymoma
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05171695 | Phase 1/2 | Thymoma | Not yet recr... | 937 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| Tirzepatide | Eli Lilly | Approved | GLP-1R | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C |